Daniele Baiz

Daniele Baiz

Auto-generated profile, based on publicly available information

Daniele Baiz

Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
SHSazzad Hassan
Sazzad Hassan
APAshok K Pullikuth
Ashok K Pullikuth
KNKyle C. Nelson
Kyle C. Nelson
AFAnabel Flores
Anabel Flores
YKYelena Karpova
Yelena Karpova
GKGeorge Kulik
George Kulik
There is accumulating evidence that continuous activation of the sympathetic nervous system due to psychosocial stress increases resistance to therapy and accelerates tumor growth via β2-adrenoreceptor signaling (ADRB2). However, the effector mechanisms appear to be specific to tumor type. Here we show that activation of ADRB2 by epinephrine, increased in response to immobilization stress, delays the loss of MCL1 apoptosis regulator (MCL1) protein expression induced by cytotoxic drugs in prostate cancer cells; and thus, increases resistance of prostate cancer xenografts to cytotoxic therapies. The effect of epinephrine on MCL1 protein depended on protein kinase A (PKA) activity, but was independent from androgen receptor expression. Furthermore, elevated blood epinephrine levels correlated positively with an increased MCL1 protein expression in human prostate biopsies. In summary, we demonstrate that stress triggers an androgen-independent antiapoptotic signaling via the ADRB2/PKA/MCL1 pathway in prostate cancer cells. Implications: Presented results justify clinical studies of ADRB2 blockers as therapeutics and of MCL1 protein expression as potential biomarker predicting efficacy of apoptosis-targeting drugs in prostate cancer.

1 January 2020 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
SFSara Ferluga
Sara Ferluga
DBDaniele Baiz
Daniele Baiz
DHDavid A Hilton
David A Hilton
CAClaire Adams
Claire Adams
EEEmanuela Ercolano
Emanuela Ercolano
CHC. Oliver Hanemann
C. Oliver Hanemann
Meningiomas are the most frequent primary brain tumors of the central nervous system. The standard of treatment is surgery and radiotherapy, but effective pharmacological options are not available yet. The well-characterised genetic background stratifies these tumors in several subgroups, thus increasing diversification. We identified EGFR-STAT1 overexpression and activation as a common identifier of these tumors. We analysed STAT1 overexpression and phosphorylation in 131 meningiomas of different grades and locations by utilising several techniques, including Western blots, qPCR and immunocytochemistry. We also silenced and overexpressed wild-type and mutant forms of the gene to assess its biological function and its network. Results were further validated by drug testing. STAT1 was found widely overexpressed in meningioma but not in the corresponding healthy controls. The protein showed a constitutive phosphorylation not dependent on the JAK/STAT pathway. STAT1 knock-down resulted in a significant reduction of cellular proliferation and deactivation of AKT and ERK1/2. STAT1 is known to be activated by EGFR, so we investigated the tyrosine kinase and found that EGFR was also constitutively phosphorylated in meningioma and was responsible for the aberrant phosphorylation of STAT1. The pharmaceutical inhibition of EGFR caused a significant reduction in cellular proliferation and of overall levels of Cyclin D1, pAKT and pERK1/2. STAT1 EGFR-dependent constitutive phosphorylation is responsible for a positive feedback loop that causes its own overexpression and consequently an increased proliferation of the tumor cells. These findings provide the rationale for further studies aiming to identify effective therapeutic options in meningioma.

3 April 2023
Verified
Other
Open access
SHSazzad Hassan
Sazzad Hassan
APAshok K Pullikuth
Ashok K Pullikuth
KNKyle C. Nelson
Kyle C. Nelson
AFAnabel Flores
Anabel Flores
YKYelena Karpova
Yelena Karpova
GKGeorge Kulik
George Kulik
S1. Epinephrine inhibits apoptosis by upregulatingMCL1in prostate cancer cells. S2.Epinephrine upregulates MCL1via the ADRB2/PKA pathway S3.C4-2shMCL1 cells with inducible expression of shRNAtargeting MCL1. S4. Effects of chemotherapy drugs on MCL1 expression in prostate cancer cells. S5. The loss of MCL1 expression in cells treated with chemotherapeuticdrugsis restored via ADRB2/PKA signaling.

3 April 2023
Verified
Other
Open access
SHSazzad Hassan
Sazzad Hassan
APAshok K Pullikuth
Ashok K Pullikuth
KNKyle C. Nelson
Kyle C. Nelson
AFAnabel Flores
Anabel Flores
YKYelena Karpova
Yelena Karpova
GKGeorge Kulik
George Kulik
There is accumulating evidence that continuous activation of the sympathetic nervous system due to psychosocial stress increases resistance to therapy and accelerates tumor growth via β2-adrenoreceptor signaling (ADRB2). However, the effector mechanisms appear to be specific to tumor type. Here we show that activation of ADRB2 by epinephrine, increased in response to immobilization stress, delays the loss of MCL1 apoptosis regulator (MCL1) protein expression induced by cytotoxic drugs in prostate cancer cells; and thus, increases resistance of prostate cancer xenografts to cytotoxic therapies. The effect of epinephrine on MCL1 protein depended on protein kinase A (PKA) activity, but was independent from androgen receptor expression. Furthermore, elevated blood epinephrine levels correlated positively with an increased MCL1 protein expression in human prostate biopsies. In summary, we demonstrate that stress triggers an androgen-independent antiapoptotic signaling via the ADRB2/PKA/MCL1 pathway in prostate cancer cells.Implications:Presented results justify clinical studies of ADRB2 blockers as therapeutics and of MCL1 protein expression as potential biomarker predicting efficacy of apoptosis-targeting drugs in prostate cancer.

3 April 2023
Verified
Other
Open access
SHSazzad Hassan
Sazzad Hassan
APAshok K Pullikuth
Ashok K Pullikuth
KNKyle C. Nelson
Kyle C. Nelson
AFAnabel Flores
Anabel Flores
YKYelena Karpova
Yelena Karpova
GKGeorge Kulik
George Kulik
There is accumulating evidence that continuous activation of the sympathetic nervous system due to psychosocial stress increases resistance to therapy and accelerates tumor growth via β2-adrenoreceptor signaling (ADRB2). However, the effector mechanisms appear to be specific to tumor type. Here we show that activation of ADRB2 by epinephrine, increased in response to immobilization stress, delays the loss of MCL1 apoptosis regulator (MCL1) protein expression induced by cytotoxic drugs in prostate cancer cells; and thus, increases resistance of prostate cancer xenografts to cytotoxic therapies. The effect of epinephrine on MCL1 protein depended on protein kinase A (PKA) activity, but was independent from androgen receptor expression. Furthermore, elevated blood epinephrine levels correlated positively with an increased MCL1 protein expression in human prostate biopsies. In summary, we demonstrate that stress triggers an androgen-independent antiapoptotic signaling via the ADRB2/PKA/MCL1 pathway in prostate cancer cells.Implications:Presented results justify clinical studies of ADRB2 blockers as therapeutics and of MCL1 protein expression as potential biomarker predicting efficacy of apoptosis-targeting drugs in prostate cancer.

3 April 2023
Verified
Other
Open access
SHSazzad Hassan
Sazzad Hassan
APAshok K Pullikuth
Ashok K Pullikuth
KNKyle C. Nelson
Kyle C. Nelson
AFAnabel Flores
Anabel Flores
YKYelena Karpova
Yelena Karpova
GKGeorge Kulik
George Kulik
S1. Epinephrine inhibits apoptosis by upregulatingMCL1in prostate cancer cells. S2.Epinephrine upregulates MCL1via the ADRB2/PKA pathway S3.C4-2shMCL1 cells with inducible expression of shRNAtargeting MCL1. S4. Effects of chemotherapy drugs on MCL1 expression in prostate cancer cells. S5. The loss of MCL1 expression in cells treated with chemotherapeuticdrugsis restored via ADRB2/PKA signaling.